As a general rule our investment focus is across B2B platform & services industries, but now and then we see a business with a consumer focus in their revenue model which drives strong B2B2C channels for sustained growth – and with our first digital MedTech investment we saw just that.
Five years on from investing into RXLive and securing co-investment from the UK and North America of more than a million dollars, we’re excited to have completed the investment cycle with an agreed secondaries sale including our syndicated investors. It’s always a tough market for any growth-stage company, both in terms of capital raising and in their efforts to generate incremental revenue & margins (ideally with both being increasingly positive!), and in the case of RXLive the energy-filled founder continued to deliver on m-o-m growth throughout the investment period. A testament to his passion for the technology he created!
An exit can take a variety of forms, where you can chalk up one more successful exit (or not!). In a market that feels the blunt end of government-led reductions in the national health budget, a MedTech that is inextricably linked with that health system can only thrive within the limitations of what that health system makes possible. With the timing now right for the business to restructure as it enters the next phase of market positioning, all stakeholders have done well to complete the exit process through a secondaries transaction that will allow us to take the next cohort of our portfolio through a similar cycle of growth. And for RXLive it’s full speed ahead with the new round of investment and a new direction.
As we enter the new year with a number of impressive scale-up businesses joining the portfolio, the agenda for investment & venture building at Axial Capital will be as active as ever.